eBook, PDF

Resistance to Proteasome Inhibitors in Cancer (eBook, PDF)

Molecular Mechanisms and Strategies to Overcome Resistance

Redaktion: Dou, Q. Ping

Beschreibung

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

Technische Details

• Geräte: PC
• ohne Kopierschutz
• Größe: 6.85MB

Barrierefreiheit

• Text-to-Speech

Autor

Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.

Produktdetails

• Verlag: Springer International Publishing
• Seitenzahl: 390
• Erscheinungstermin: 16. September 2014
• Englisch
• ISBN-13: 9783319067520
• Artikelnr.: 43788299